Source:http://linkedlifedata.com/resource/pubmed/id/10351140
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1999-5-5
|
| pubmed:abstractText |
Immune thrombocytopenic purpura (ITP) is a disorder caused by accelerated destruction of antibody-coated platelets in the reticuloendothelial system (RES), especially the spleen. Inhibition of RES function following intravenous administration of high-dose immunoglobulin G (IVIG) or intravenous anti-D leads to rapid, albeit usually temporary, reversal of thrombocytopenia in the majority of children and adults with ITP. In emergency situations high-dose IVIG is preferred over anti-D because of the more rapid rate of platelet response; for maintenance therapy in Rh positive ITP patients (e.g. children with chronic ITP pre-splenectomy) anti-D is preferred because of its comparable efficacy to IVIG plus ease of administration and lower cost. In children with typical acute ITP and platelet counts < 20 x 10(9)/L IVIG is preferred over anti-D; however other approaches in this patient cohort should be considered before high-dose IVIG, specifically careful observation alone with therapy given only to children with clinically significant haemorrhage or short course oral prednisone at a starting dose of approximately 4 mg/kg/day. Studies are required to define the short and longer term effects of both IVIG and anti-D on the immune system in order to plan more rational use of these immunomodulatory therapies in this model autoimmune disorder.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
T
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0955-3886
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
19
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
279-88
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:10351140-Acute Disease,
pubmed-meshheading:10351140-Adolescent,
pubmed-meshheading:10351140-Adult,
pubmed-meshheading:10351140-Autoimmune Diseases,
pubmed-meshheading:10351140-Child,
pubmed-meshheading:10351140-Clinical Trials as Topic,
pubmed-meshheading:10351140-Cohort Studies,
pubmed-meshheading:10351140-Female,
pubmed-meshheading:10351140-Hemorrhage,
pubmed-meshheading:10351140-Humans,
pubmed-meshheading:10351140-Immunity, Maternally-Acquired,
pubmed-meshheading:10351140-Immunoglobulins, Intravenous,
pubmed-meshheading:10351140-Immunosuppressive Agents,
pubmed-meshheading:10351140-Infant, Newborn,
pubmed-meshheading:10351140-Isoantibodies,
pubmed-meshheading:10351140-Platelet Count,
pubmed-meshheading:10351140-Pregnancy,
pubmed-meshheading:10351140-Pregnancy Complications,
pubmed-meshheading:10351140-Purpura, Thrombocytopenic, Idiopathic,
pubmed-meshheading:10351140-Spherocytosis, Hereditary
|
| pubmed:year |
1998
|
| pubmed:articleTitle |
Intravenous immunoglobulin G and anti-D as therapeutic interventions in immune thrombocytopenic purpura.
|
| pubmed:affiliation |
Division of Hematology/Oncology, Hospital for Sick Children, Toronto, Canada. victor.blanchette@sickkids.on.ca
|
| pubmed:publicationType |
Journal Article,
Comparative Study
|